# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### Form 8-K

# Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 10/19/2006

# Tercica, Inc.

(Exact name of registrant as specified in its charter)

Commission File Number: 000-50461

Delaware (State or other jurisdiction of incorporation) 26-0042539 (IRS Employer Identification No.)

### 2000 Sierra Point Parkway

Suite 400

Brisbane, CA 94005

(Address of principal executive offices, including zip code)

(650) 624-4900

(Registrant s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: TERCICA INC - Form 8-K

Information to be included in the report

#### Item 8.01. Other Events

On October 18, 2006, the Company received 9,500,000 Euros (\$11,800,900) from Ipsen, which represents the upfront Increlex licensing payment of 10,000,000 Euros, net of withholding taxes.

#### Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Tercica, Inc.

Date: October 19, 2006 By: /s/ Stephen N. Rosenfield

Stephen N. Rosenfield Executive Vice President of Legal Affairs